SCHEMBL1090866

SCHEMBL1090866

O=[N+]([O-])c1ccc(S(=O)(=O)N2CCCC(N3CCC(Nc4nccc(N5CCCCCC5)n4)C3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HRH4 Q9H3N8 3/20 0.41
▸ IKBKB O14920 8/20 0.40
▸ CHUK O15111 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPK8 P45983 2/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ BRAF P15056 1/20 0.39
▸ ALK Q9UM73 1/20 0.38
▸ MAPK9 P45984 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ MAPK11 Q15759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1091257 0.97 ALDH1A1 (0.45) CXCR4ALDH1A1SMN1; SMN2MEN1MAPT
SCHEMBL1090072 0.96 ALDH1A1 (0.47) CXCR4ALDH1A1SMN1; SMN2MEN1MAPT
SCHEMBL1090674 0.92 CXCR4 (0.46) CXCR4ALDH1A1SMN1; SMN2MEN1MAPT
SCHEMBL1090179 0.89 ALDH1A1 (0.46) CXCR4ALDH1A1SMN1; SMN2MEN1MAPT
SCHEMBL1089055 0.89 CXCR4 (0.47) CXCR4ALDH1A1MAPK1HRH4IKBKB
SCHEMBL1089328 0.89 CXCR4 (0.55) CXCR4ALDH1A1SMN1; SMN2MEN1MAPK1
SCHEMBL1090435 0.88 ALDH1A1 (0.48) CXCR4ALDH1A1SMN1; SMN2MEN1MAPT
SCHEMBL1090003 0.87 CXCR4 (0.45) CXCR4ALDH1A1HRH4IKBKBLMNA
SCHEMBL1090409 0.87 TSHR (0.45) CXCR4ALDH1A1HTTHRH4IKBKB
SCHEMBL1090779 0.87 CXCR4 (0.45) CXCR4ALDH1A1MEN1KMT2AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 — — US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 — — US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 — — US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 — — US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 — — US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885ALDH1A1 916/4885SMN1; SMN2 1918/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885ALDH1A1 916/4885SMN1; SMN2 1918/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885ALDH1A1 916/4885SMN1; SMN2 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback